ICON plc to Present at the William Blair 45th Annual Growth Stock Conference
DUBLIN--(BUSINESS WIRE)-- ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the William Blair 45th Annual Growth Stock Conference on Wednesday, June 4, 2025 at 10.40 am CT.
Any changes to this event and links to the live webcast (where available) will be posted on the Investor section of our website under ' Events '.
About ICON plc
ICON plc is a world-leading clinical research organisation powered by healthcare intelligence. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON employed approximately 41,250 employees in 97 locations in 55 countries as at March 31, 2025. For further information about ICON, visit: www.iconplc.com.
This press release contains forward-looking statements, including statements about our financial guidance. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, as well as other economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, F-4, S-8, F-3 and certain other reports, which are available on the SEC's website at http://www.sec.gov.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Drug maker Indivior to abandon London stock market for the US
Drug maker Indivior has announced plans to delist its shares from the London Stock Exchange (LSE), marking the latest company to abandon the UK market for the US. However, the LSE welcomes Anglo-American's platinum spin-off Valterra after becoming independent from the mining giant. Indivior's exit comes after the company moved its primary listing to the US's Nasdaq index last year. It said cancelling the secondary listing in London eliminates 'cost and complexity' and better reflects the business – with more than 80% of its revenues generated in the US. It also said liquidity on the Nasdaq now 'far outweighs' that of the LSE with a greater level of trading. The US-based pharmaceutical firm makes prescription medicines to treat opioid addiction, and has a market capitalisation of £1.2 billion. 'A single primary listing on Nasdaq best reflects the profile of Indivior's business,' chairman David Wheadon said. 'We appreciate the support received from shareholders for this initiative and look forward to capitalising on the expected benefits of this move, including reductions in cost and complexity.' The LSE faced the largest exodus of companies since the global financial crisis in 2024, according to EY analysis. There were 88 companies to delist or transfer their primary listing from the main market – the most since 2009. At the same time, the LSE struggled to attract as many new companies to fill the gaps – with 18 new listings in total last year. Nevertheless, Indivior's exit, which will take effect from July 25, comes as Valterra Platinum makes its debut on the London market. Anglo American spun off its platinum business into the new entity, which has become the world's most valuable producer of the metal. Valterra will have its secondary listing on the LSE, with its primary on the Johannesburg Stock Exchange. Duncan Wanblad, Anglo American's chief executive, said: 'Valterra Platinum has been a major part of the company for many years but now is the right time for it to optimise its value creation prospects on an independent path – it's an outstanding business and team and I have every confidence that Valterra Platinum will thrive as a leader in the global platinum group metals industry.' Sign in to access your portfolio
Yahoo
37 minutes ago
- Yahoo
Ollie's (OLLI) Reports Q1: Everything You Need To Know Ahead Of Earnings
Discount retail company Ollie's Bargain Outlet (NASDAQ:OLLI) will be announcing earnings results tomorrow before the bell. Here's what you need to know. Ollie's missed analysts' revenue expectations by 1.2% last quarter, reporting revenues of $667.1 million, up 2.8% year on year. It was a mixed quarter for the company, with an impressive beat of analysts' gross margin estimates but full-year EPS guidance missing analysts' expectations. Is Ollie's a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Ollie's revenue to grow 11.3% year on year to $566.2 million, in line with the 10.8% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.71 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Ollie's has missed Wall Street's revenue estimates four times over the last two years. Looking at Ollie's peers in the discount retailer segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Ross Stores delivered year-on-year revenue growth of 2.6%, beating analysts' expectations by 0.5%, and TJX reported revenues up 5.1%, topping estimates by 0.7%. Ross Stores traded down 9.8% following the results while TJX was also down 4%. Read our full analysis of Ross Stores's results here and TJX's results here. There has been positive sentiment among investors in the discount retailer segment, with share prices up 9.8% on average over the last month. Ollie's stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $125.88 (compared to the current share price of $110). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
38 minutes ago
- Yahoo
Couchbase (BASE) Q1 Earnings: What To Expect
Database as a service company Couchbase (NASDAQ: BASE) will be reporting results tomorrow after the bell. Here's what to expect. Couchbase beat analysts' revenue expectations by 3.1% last quarter, reporting revenues of $54.92 million, up 9.6% year on year. It was a satisfactory quarter for the company, with an impressive beat of analysts' billings estimates but full-year guidance of slowing revenue growth. Is Couchbase a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Couchbase's revenue to grow 8.2% year on year to $55.56 million, slowing from the 25.2% increase it recorded in the same quarter last year. Adjusted loss is expected to come in at -$0.08 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Couchbase has missed Wall Street's revenue estimates twice over the last two years. Looking at Couchbase's peers in the data storage segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Commvault Systems delivered year-on-year revenue growth of 23.2%, beating analysts' expectations by 4.8%, and Snowflake reported revenues up 25.7%, topping estimates by 3.4%. Commvault Systems's stock price was unchanged after the resultswhile Snowflake was up 13.5%. Read our full analysis of Commvault Systems's results here and Snowflake's results here. There has been positive sentiment among investors in the data storage segment, with share prices up 7.6% on average over the last month. Couchbase's stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $20.81 (compared to the current share price of $17.61). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
